CMTAWinter2023webspreads

…approved ASO-based treatments for several neuromuscular conditions, including spinal muscular atrophy (SMA) and familial amyloid neuropathy. The study uses the same chemistry as the SMA treatment (Nusinersen) to accelerate potential…

STAR_Webinar_Transcript

…with CMT. Nevertheless, for people like you and for me, 10 years feels like an eternity when there are still no viable treatments for CMT. On the other hand, 10…

Managing_Neuropathic_Pain_Dr_Steven_Scherer

…calcium channel a2-d ligands (i.e., gabapentin and pregabalin), and topical lidocaine” were considered first-line treatments, with opioids as “generally second-line treatments”. “Third-line treatments that could also be used as second-line…

2022 Annual Report_spreads

…leading academic labs, clinical centers and pharmaceutical and biotech companies to advance scientific knowledge, increase clinical trial readiness and accelerate progress towards treatments for CMT. Today, CMTA-STAR is the largest…

NeuroMeds

…placement of some agents. As with any treatment, the risk of neuropathy exacerbation must be weighed against expected treatment benefits and available equivalent, alternative treatments. Despite the limitations of this…

CMT Respiratory Impairment Final

…Common treatment approaches for restrictive and obstructive lung disease are basically oxygen as needed, an inhaler or two, and nebulizer treatments. Oxygen is used to treat hypoxemia/hypoxia, and inhalers/nebulizer treatments…

2019_Spring_CMTA_Report

…mice led to increased protein levels and tested whether treatment at later stages of the disease led to improvement like that seen for treatment in the early stages. The target…

2019_Spring_CMTA_Report

…mice led to increased protein levels and tested whether treatment at later stages of the disease led to improvement like that seen for treatment in the early stages. The target…